Polypharmacy in Older Adults: The Hazard of Hospitalization and Mortality is Mediated by Potentially Inappropriate Prescriptions, Findings From the Moli-sani Study

Int J Public Health. 2024 Oct 24:69:1607682. doi: 10.3389/ijph.2024.1607682. eCollection 2024.

Abstract

Objectives: We evaluated the impact of polypharmacy on the health of community-dwelling older adults.

Methods: We prospectively analyzed 5,631 individuals from the Moli-sani study (51% men, aged ≥65 years, recruitment 2005-2010, follow-up 2005-2020). Exposure was categorized as chronic polypharmacy therapy (C-PT; ≥5 therapeutic groups and >2 defined daily doses (DDDs)) or non-chronic polypharmacy therapy (NC-PT; polypharmacy but ≤2 DDDs). Hospitalization and mortality were the main outcomes. The mediating role of potentially inappropriate prescriptions (PIP) was examined.

Results: Compared to individuals not on polypharmacy, those in NC-PT and C-PT had higher hazards of mortality [21% (95% CI 7%-37%) and 30% (16%-46%), respectively] and hospitalization [39% (28%-51%) and 61% (49%-75%), respectively]. Similar results were found for cardiovascular outcomes. PIP mediated the association between polypharmacy and outcomes, with mediation effects ranging from 13.6% for mortality to 6.0% for hospitalization. Older adults without multimorbidity experienced the same harm from multiple medications as those with multimorbidity.

Conclusion: Polypharmacy is associated with a higher hazard of mortality and hospitalization, with PIP playing an important role. Addressing "medication without harm" requires assessing the appropriateness of drug prescriptions and monitoring for adverse effects.

Keywords: elderly; hospitalization; mortality; polypharmacy; potentially inappropriate prescriptions.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Inappropriate Prescribing* / statistics & numerical data
  • Independent Living
  • Italien
  • Male
  • Mortality
  • Polypharmacy*
  • Potentially Inappropriate Medication List
  • Prospective Studies

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The enrollment phase of the Moli-sani study was supported by research grants from the Pfizer Foundation (Rome, Italy), the Italian Ministry of University and Research (MIUR, Rome, Italy)–Programma Triennale di Ricerca, Decreto no. 1588 and the Instrumentation Laboratory, Milan, Italy. The present study was funded by the AIFA - The Italian Medicines Agency - Italy (Ricerca Indipendente AIFA-2016-02364690). The present analyses were partially supported by Next-Generation EU - “Age-It - Ageing well in an ageing society” project (PE0000015), National Recovery and Resilience Plan (NRRP) - PE8 - Mission 4, C2, Intervention 1.3. The funders had no role in the study design, collection, analysis, and interpretation of data, nor in the writing of the manuscript or in the decision to submit the article for publication. All Authors were and are independent of the funders.